Bio-Rad wins appeal in 10x Genomics patent infringement ruling

By The Science Advisory Board staff writers

August 5, 2020 -- Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed a patent that had been exclusively licensed to Bio-Rad by the University of Chicago.

The Court of Appeals also upheld the lower court's finding for $23.9 million in monetary damages, awarding Bio-Rad a 15% royalty on past and future sales, and a permanent injunction against 10x's Single Cell 3' gene expression products, Single Cell assay for transposase accessible chromatin (ATAC)-seq products, and Single Cell V(D)J products that were found to infringe U.S. Patent 8,889,083, Bio-Rad said.

However, the Court of Appeals also withdrew the District Court's injunction with respect to 10x's Linked-Read and copy number variation (CNV) product lines and reversed the District Court's decision on infringement of two other patents asserted by Bio-Rad. The company said that it does not believe these aspects of the decision will have a material impact on the overall result and is evaluating its options for further review.

Bio-Rad's Q2 revenue drops
Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter as well as for the first half of the year.
Bio-Rad posts increased Q1 revenue during pandemic
For the quarter revenue increased to $571.6 million, compared with $554 million in the first quarter of 2019. Meanwhile, net income in the first...
Bio-Rad acquires single-cell analysis company
Bio-Rad Laboratories has acquired Celsee, a company that offers instruments and consumables for single-cell analysis.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter